Outlook Therapeutics (NASDAQ:OTLK) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Outlook Therapeutics (NASDAQ:OTLK) released its earnings results on Friday. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Trading Up 18.2 %

Shares of OTLK stock opened at $2.01 on Friday. The company has a 50 day simple moving average of $3.81 and a two-hundred day simple moving average of $5.89. The stock has a market cap of $47.55 million, a P/E ratio of -0.19 and a beta of 0.46. Outlook Therapeutics has a 12 month low of $0.87 and a 12 month high of $12.85.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. BTIG Research decreased their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Finally, Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.73.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.